BioTime Inc. Subsidiary, AgeX Therapeutics, Closes $5 Million Strategic Investment From Juvenescence; Co. Says Juvenescence Investment Combined With Other Capital Raising Efforts Provide Sufficient Capital For Continued Development Of Programs Into 2020
Benzinga Newsdesk